Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 226

1.

Kras(G12D) and Nkx2-1 haploinsufficiency induce mucinous adenocarcinoma of the lung.

Maeda Y, Tsuchiya T, Hao H, Tompkins DH, Xu Y, Mucenski ML, Du L, Keiser AR, Fukazawa T, Naomoto Y, Nagayasu T, Whitsett JA.

J Clin Invest. 2012 Dec;122(12):4388-400. doi: 10.1172/JCI64048. Epub 2012 Nov 12.

2.

KRAS and NKX2-1 Mutations in Invasive Mucinous Adenocarcinoma of the Lung.

Hwang DH, Sholl LM, Rojas-Rudilla V, Hall DL, Shivdasani P, Garcia EP, MacConaill LE, Vivero M, Hornick JL, Kuo FC, Lindeman NI, Dong F.

J Thorac Oncol. 2016 Apr;11(4):496-503. doi: 10.1016/j.jtho.2016.01.010. Epub 2016 Jan 30.

3.

Nkx2-1 represses a latent gastric differentiation program in lung adenocarcinoma.

Snyder EL, Watanabe H, Magendantz M, Hoersch S, Chen TA, Wang DG, Crowley D, Whittaker CA, Meyerson M, Kimura S, Jacks T.

Mol Cell. 2013 Apr 25;50(2):185-99. doi: 10.1016/j.molcel.2013.02.018. Epub 2013 Mar 21.

4.

Inactivating mutations and hypermethylation of the NKX2-1/TTF-1 gene in non-terminal respiratory unit-type lung adenocarcinomas.

Matsubara D, Soda M, Yoshimoto T, Amano Y, Sakuma Y, Yamato A, Ueno T, Kojima S, Shibano T, Hosono Y, Kawazu M, Yamashita Y, Endo S, Hagiwara K, Fukayama M, Takahashi T, Mano H, Niki T.

Cancer Sci. 2017 Sep;108(9):1888-1896. doi: 10.1111/cas.13313. Epub 2017 Jul 29.

5.

Unique Genetic and Survival Characteristics of Invasive Mucinous Adenocarcinoma of the Lung.

Shim HS, Kenudson M, Zheng Z, Liebers M, Cha YJ, Hoang Ho Q, Onozato M, Phi Le L, Heist RS, Iafrate AJ.

J Thorac Oncol. 2015 Aug;10(8):1156-62. doi: 10.1097/JTO.0000000000000579.

6.

Thyroid transcription factor-1-regulated microRNA-532-5p targets KRAS and MKL2 oncogenes and induces apoptosis in lung adenocarcinoma cells.

Griesing S, Kajino T, Tai MC, Liu Z, Nakatochi M, Shimada Y, Suzuki M, Takahashi T.

Cancer Sci. 2017 Jul;108(7):1394-1404. doi: 10.1111/cas.13271. Epub 2017 Jun 10.

7.

Foxm1 transcription factor is required for the initiation of lung tumorigenesis by oncogenic Kras(G12D.).

Wang IC, Ustiyan V, Zhang Y, Cai Y, Kalin TV, Kalinichenko VV.

Oncogene. 2014 Nov 13;33(46):5391-6. doi: 10.1038/onc.2013.475. Epub 2013 Nov 11.

PMID:
24213573
8.

Suppression of lung adenocarcinoma progression by Nkx2-1.

Winslow MM, Dayton TL, Verhaak RG, Kim-Kiselak C, Snyder EL, Feldser DM, Hubbard DD, DuPage MJ, Whittaker CA, Hoersch S, Yoon S, Crowley D, Bronson RT, Chiang DY, Meyerson M, Jacks T.

Nature. 2011 May 5;473(7345):101-4. doi: 10.1038/nature09881. Epub 2011 Apr 6.

9.

FOXM1 activates AGR2 and causes progression of lung adenomas into invasive mucinous adenocarcinomas.

Milewski D, Balli D, Ustiyan V, Le T, Dienemann H, Warth A, Breuhahn K, Whitsett JA, Kalinichenko VV, Kalin TV.

PLoS Genet. 2017 Dec 21;13(12):e1007097. doi: 10.1371/journal.pgen.1007097. eCollection 2017 Dec.

10.

Transcription factor and microRNA interactions in lung cells: an inhibitory link between NK2 homeobox 1, miR-200c and the developmental and oncogenic factors Nfib and Myb.

Tagne JB, Mohtar OR, Campbell JD, Lakshminarayanan M, Huang J, Hinds AC, Lu J, Ramirez MI.

Respir Res. 2015 Feb 13;16:22. doi: 10.1186/s12931-015-0186-6.

11.

Associations between mutations and histologic patterns of mucin in lung adenocarcinoma: invasive mucinous pattern and extracellular mucin are associated with KRAS mutation.

Kadota K, Yeh YC, D'Angelo SP, Moreira AL, Kuk D, Sima CS, Riely GJ, Arcila ME, Kris MG, Rusch VW, Adusumilli PS, Travis WD.

Am J Surg Pathol. 2014 Aug;38(8):1118-27. doi: 10.1097/PAS.0000000000000246.

12.

Identification of tumorigenic cells in Kras(G12D)-induced lung adenocarcinoma.

Cho HC, Lai CY, Shao LE, Yu J.

Cancer Res. 2011 Dec 1;71(23):7250-8. doi: 10.1158/0008-5472.CAN-11-0903. Epub 2011 Nov 16.

13.

Airway epithelial transcription factor NK2 homeobox 1 inhibits mucous cell metaplasia and Th2 inflammation.

Maeda Y, Chen G, Xu Y, Haitchi HM, Du L, Keiser AR, Howarth PH, Davies DE, Holgate ST, Whitsett JA.

Am J Respir Crit Care Med. 2011 Aug 15;184(4):421-9. doi: 10.1164/rccm.201101-0106OC.

14.

PIK3CA(H1047R) Accelerates and Enhances KRAS(G12D)-Driven Lung Tumorigenesis.

Green S, Trejo CL, McMahon M.

Cancer Res. 2015 Dec 15;75(24):5378-91. doi: 10.1158/0008-5472.CAN-15-1249. Epub 2015 Nov 13.

15.

Loss of Somatostatin Receptor Subtype 2 Promotes Growth of KRAS-Induced Pancreatic Tumors in Mice by Activating PI3K Signaling and Overexpression of CXCL16.

Chalabi-Dchar M, Cassant-Sourdy S, Duluc C, Fanjul M, Lulka H, Samain R, Roche C, Breibach F, Delisle MB, Poupot M, Dufresne M, Shimaoka T, Yonehara S, Mathonnet M, Pyronnet S, Bousquet C.

Gastroenterology. 2015 Jun;148(7):1452-65. doi: 10.1053/j.gastro.2015.02.009. Epub 2015 Feb 13.

PMID:
25683115
16.

Protein kinase Cα suppresses Kras-mediated lung tumor formation through activation of a p38 MAPK-TGFβ signaling axis.

Hill KS, Erdogan E, Khoor A, Walsh MP, Leitges M, Murray NR, Fields AP.

Oncogene. 2014 Apr 17;33(16):2134-44. doi: 10.1038/onc.2013.147. Epub 2013 Apr 22.

17.

Loss of p53 attenuates the contribution of IL-6 deletion on suppressed tumor progression and extended survival in Kras-driven murine lung cancer.

Tan X, Carretero J, Chen Z, Zhang J, Wang Y, Chen J, Li X, Ye H, Tang C, Cheng X, Hou N, Yang X, Wong KK.

PLoS One. 2013 Nov 15;8(11):e80885. doi: 10.1371/journal.pone.0080885. eCollection 2013.

18.

Lepidic predominant adenocarcinoma and invasive mucinous adenocarcinoma of the lung exhibit specific mucin expression in relation with oncogenic drivers.

Duruisseaux M, Antoine M, Rabbe N, Rodenas A, Mc Leer-Florin A, Lacave R, Poulot V, Duchêne B, Van Seuningen I, Cadranel J, Wislez M.

Lung Cancer. 2017 Jul;109:92-100. doi: 10.1016/j.lungcan.2017.05.007. Epub 2017 May 10.

PMID:
28577958
19.

DNA vaccine elicits an efficient antitumor response by targeting the mutant Kras in a transgenic mouse lung cancer model.

Weng TY, Yen MC, Huang CT, Hung JJ, Chen YL, Chen WC, Wang CY, Chang JY, Lai MD.

Gene Ther. 2014 Oct;21(10):888-96. doi: 10.1038/gt.2014.67. Epub 2014 Jul 31.

PMID:
25077772
20.

MEK1/2 inhibition elicits regression of autochthonous lung tumors induced by KRASG12D or BRAFV600E.

Trejo CL, Juan J, Vicent S, Sweet-Cordero A, McMahon M.

Cancer Res. 2012 Jun 15;72(12):3048-59. doi: 10.1158/0008-5472.CAN-11-3649. Epub 2012 Apr 17.

Supplemental Content

Support Center